A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.

Exclusion Criteria

• •1. Previously exposed to regorafenib, furoquintinib, TAS-102, PD-1 inhibitors, or targeted drugs or immunotherapy for HER2 amplification, BRAF V600E mutation, and NTRK gene fusion.
• •2. Previously rechallenged or retreated by oxaliplatin or irinotecan after progression from chemotherapy regimens including oxaliplatin and irinotecan.
• •3. Participate in another interventional clinical study at the same time, unless in the follow-up stage of intervention study.
• •4. Proposed to use a treatment regimen containing regorafenib, furquintinib, and trifluridine, but has any problems obstacling oral drugs, such as inability to swallow, chronic diarrhea and intestinal obstruction et al.
• •5. Disagree to take contraceptive measures during the study treatment period or within 6 months after the end of the study treatment period.
• •6. Has other primary malignant tumor history, unless non-melanoma skin cancer or lentigo maligna or carcinoma in situ with sufficient treatment and no disease recurrence.
• •7. Has the history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
• •8. Has concomitant diseases that seriously endanger patient safety or affect patient completion of the study.
• •9. Has other problems that is not suitable for clinical research.